HOME >> BIOLOGY >> NEWS
Progesterone therapy and preterm birth: More evidence helps identify women who can benefit

WHITE PLAINS, N.Y., AUG. 2, 2005 Two major studies published today in The New England Journal of Medicine can help doctors better identify pregnant women at risk for preterm delivery who can benefit from progesterone treatment, the March of Dimes Foundation said today.

In one large multi-center trial led by Eduardo B. Fonseca, M.D., women with short cervix (most of whom had no prior history of preterm birth) who received progesterone suppository treatment between 24 and 34 weeks gestation had a greatly reduced rate of preterm birth.

Another large multi-center trial led by Dwight J. Rouse, M.D., found that weekly injections of 17P (17 alpha-hydroxyprogesterone caproate, a derivative of progesterone) between 16 and 35 weeks gestation did not reduce the rate of preterm birth among women carrying twins.

Premature birth is a growing problem in the United States and a leading killer of newborns, said Michael Katz, senior vice president for Research and Global Programs of the March of Dimes. With this new information, physicians will have a better idea of how to identify those women who are most likely to benefit from progesterone treatment from those who are not.

Dr. Katz noted that pathways to preterm birth may differ substantially between singleton and twin gestations. For example, progesterone may be more effective against some pathway that does not involve the uterine over-distention seen in twin pregnancy.

We need more research into the underlying causes of prematurity to help women with other risk factors, Dr. Katz said.


'"/>

Contact: Elizabeth Lynch
elynch@marchofdimes.com
914-997-4286
March of Dimes Foundation
1-Aug-2007


Page: 1

Related biology news :

1. Progesterone injections do not prevent preterm birth in twin pregnancies
2. Testosterone replacement therapy: How safe for aging men?
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Stem cell therapy rescues motor neurons in ALS model
7. Study identifies new gene therapy tools for inherited blindness
8. Breast cancer and hormone therapy -- A looking-glass mirror?
9. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
10. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... , ... August 19, 2020 , ... ... LLC and SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than twenty ... recently published book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research ...
(Date:8/21/2020)... ... August 20, 2020 , ... ... Hassan Movahhed , a Clinical Operations executive with expertise in clinical trial planning ... the firm as an Expert Consultant. Throughout his career, Mr. Movahhed has helped ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently announced its ... public health agencies of all sizes. With a focus on tracking symptoms and ... appropriate health care, Mosio helps public health departments automate communications and provide more ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... ... 2020 , ... DuPont Nutrition & Biosciences announced today the ... plant operation will provide the local animal production industry with customized solutions according ... improve the flexibility of our offerings to the Chinese animal nutrition market,” said ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... is making available for free its new white paper – Simulated Transport ... testing into today’s biologics licensing application (BLA). In response, Modality Solutions shares ...
(Date:8/3/2020)... ... , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions ... as MediVet Biologics since its formation in 2016, the company is relaunching itself under ... build on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... combine up to three different materials for use with CRM, neurostimulation, vascular, and ... three materials to meet specific design requirements, performance, and cost criteria; especially where ...
Breaking Biology Technology:
Cached News: